SLC3A2 and neoplasm: Tumor-to-muscle ratios (16.8 ± 0.7 or 14.4 ± 0.9 vs. 3.6 ± 0.3%ID/g, mean ± SD) were 4.7 or 4.0 and tumor-to-blood ratios (16.8 ± 0.7 or 14.4 ± 0.9 vs. 6.6 ± 0.4%ID/g) 2.5 or 2.2 for the MM1SLAT1/CD98hc or the MM1Sev/ev xenograft, respectively, as determined from the dynamic PET-scan at the 30–40 min frame.